ProCE Banner Activity

New Developments in Advanced Systemic Mastocytosis From ASH 2021

Clinical Thought
Advanced systemic mastocytosis is a rare diagnosis, yet treatment options are increasing with new FDA approvals. In this commentary, I review current treatments and the most clinically important studies on advanced systemic mastocytosis from ASH 2021.

Released: February 18, 2022

Expiration: February 17, 2023

No longer available for credit.

Share

Faculty

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Blueprint Medicines

Faculty Disclosure

Primary Author

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received funds for research support from AbbVie, Blueprint, GlycoMimetics, and Novartis and consulting fees from AbbVie, Agios, Amgen, Autolus, Blueprint, Forty Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda.